Bayer/Regeneron: Typically Rich, Extra Regional

Regeneron Pharmaceuticals' October 18th deal with Bayer is the perfect case-study for observers of today's biopharma sector: high-value, ex-US only, specialist, and with a nice split-indication twist in its tail.